Join Calluna Pharma on our mission to revolutionize the treatment of inflammatory and fibrotic diseases. With a robust pipeline, seasoned leadership, and strategic alliances, help us reshape the treatment landscape for the better.
Total raised: $81.93M
Investors 2
| Date | Name | Website |
| 24.01.2024 | Forbion | forbion.co... |
| 02.04.2024 | Sarsia | sarsia.com |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 24.01.2024 | Series A | $81.93M | Forbion |
Mentions in press and media 4
| Date | Title | Description |
| 24.01.2024 | Calluna Pharma Raises €75M in Series A Financing | Calluna Pharma, an Oslo, Norway-based clinical stage company formed from the merger of Oxitope Pharma and Arxx Therapeutics, raised €75M in Series A funding. The round was led by Forbion, with participation from Norwegian investors Sarsia, ... |
| 23.01.2024 | Calluna Pharma launches and announces EUR 75 million Series A financing to develop novel therapies for inflammatory and fibrotic diseases | · Clinical stage company formed from the merger of Oxitope Pharma and Arxx Therapeutics · Calluna Pharma has a pipeline of selective antibodies targeting immunological diseases · New company to complete multiple clinical proofs-of-concept, ... |
| 23.01.2024 | Forbion announces 75 million EUR Series A financing in Calluna Pharma | • Clinical stage company formed from the merger of Oxitope Pharma and Arxx Therapeutics to develop novel therapies for inflammatory and fibrotic diseases • Calluna Pharma has a pipeline of selective antibodies targeting immunological diseas... |
| - | Calluna Pharma | “Join Calluna Pharma on our mission to revolutionize the treatment of inflammatory and fibrotic diseases. With a robust pipeline, seasoned leadership, and strategic alliances, help us reshape the treatment landscape for the better.” |